News

Approximately 20 institutions across Europe, the US, Canada and Latin America are expected to participate in the study. The trial will examine the efficacy and safety of two

Under the prior terms of the merger agreement, completion of the merger was conditioned on the receipt of an opinion from each party’s counsel to the effect that

Under the terms of the cooperative R&D agreement, National Institute of Neurological Diseases and Stroke (NINDS) will deliver NeoPharm’s proprietary drug, Cintredekin Besudotox (IL13-PE38QQR) (IL-13), in conjunction with

The new China facility is said to position Charles River as the strategic partner of choice to fully support clients’ global drug development needs. James Foster, president, chairman

The Phase I double-blind, placebo-controlled trial of CCX025 is being conducted in healthy male and female volunteers to evaluate the safety, tolerability and pharmacokinetics of CCX025 over a

New corporate investors Medtronic and Itochu join existing investors St Jude Medical, Adams Street Partners, The Carlyle Group, Essex Woodlands, Kaiser Permanente Ventures, Spring Ridge Ventures and others.

The study is largely funded by the National Institute on Drug Abuse and will be run jointly by the New York State Psychiatric Institute and Columbia University. The

The Phase IIa multi-center, open-label study enrolled 32 subjects and was conducted at 12 US sites. Study patients received 6R-BH4 at 2.5mg/kg, 5mg/kg, 10mg/kg and 20mg/kg for four

The project is sponsored by Simdat – a program funded by the European Commission under the Information Society Technologies Programme designed to test and enhance Grid data technology